JAG1 and ovarian carcinoma: It has been shown that JAG1 is abnormally expressed in various cancers, including acute lymphoblastic leukemia, gastric cancer, breast and ovarian cancer, which affects tumor progression and metastasis, and it has been found that 15D11, a targeting drug for JAG1, can enhance the sensitivity of tumor chemotherapy and reduce bone metastasis, with very mild side effects 93.